{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:56Z","timestamp":1786979936033,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Hope Run Special Fund of Cancer Foundation of China","award":["LC2018L04"],"award-info":[{"award-number":["LC2018L04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00277-023-05559-x","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T18:01:35Z","timestamp":1701453695000},"page":"869-883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS"],"prefix":"10.1007","volume":"103","author":[{"given":"Zheng","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5663-6006","authenticated-orcid":false,"given":"Xiaoli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"issue":"7","key":"5559_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","volume":"92","author":"JO Armitage","year":"2017","unstructured":"Armitage JO (2017) The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol 92(7):706\u2013715","journal-title":"Am J Hematol"},{"issue":"7","key":"5559_CR2","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei M et al (2018) The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 103(7):1191\u20131197","journal-title":"Haematologica"},{"issue":"5","key":"5559_CR3","first-page":"e202","volume":"19","author":"H Chen","year":"2022","unstructured":"Chen H et al (2022) The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients. Asia Pac J Clin Oncol 19(5):e202\u2013e214","journal-title":"Asia Pac J Clin Oncol"},{"key":"5559_CR4","doi-asserted-by":"publisher","first-page":"607145","DOI":"10.3389\/fonc.2021.607145","volume":"11","author":"Z Chen","year":"2021","unstructured":"Chen Z et al (2021) Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified. Front Oncol 11:607145","journal-title":"Front Oncol"},{"key":"5559_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-99716-2_4","volume":"176","author":"A Oluwasanjo","year":"2019","unstructured":"Oluwasanjo A et al (2019) Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Cancer Treat Res 176:83\u201398","journal-title":"Cancer Treat Res"},{"issue":"13","key":"5559_CR6","doi-asserted-by":"publisher","first-page":"e25194","DOI":"10.1097\/MD.0000000000025194","volume":"100","author":"X Liang","year":"2021","unstructured":"Liang X et al (2021) Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma. Medicine (Baltimore) 100(13):e25194","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"5559_CR7","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474\u20132479","journal-title":"Blood"},{"issue":"16","key":"5559_CR8","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24(16):2472\u20132479","journal-title":"J Clin Oncol"},{"issue":"12","key":"5559_CR9","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117(12):3402\u20133408","journal-title":"Blood"},{"issue":"11","key":"5559_CR10","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ et al (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 91(11):1096\u20131101","journal-title":"Am J Hematol"},{"issue":"Suppl 2","key":"5559_CR11","doi-asserted-by":"publisher","first-page":"S394","DOI":"10.1016\/S2152-2650(22)01568-3","volume":"22","author":"Y Wang","year":"2022","unstructured":"Wang Y et al (2022) MCL-027 prognostic role of event-free survival at 24 months (EFS24) in newly diagnosed mantle cell lymphoma (MCL). Clin Lymphoma Myeloma Leuk 22(Suppl 2):S394","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"5559_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32(10):1066\u20131073","journal-title":"J Clin Oncol"},{"issue":"36","key":"5559_CR13","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","volume":"35","author":"MJ Maurer","year":"2017","unstructured":"Maurer MJ et al (2017) International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol 35(36):4019\u20134026","journal-title":"J Clin Oncol"},{"issue":"5","key":"5559_CR14","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/hon.2687","volume":"37","author":"K Wudhikarn","year":"2019","unstructured":"Wudhikarn K et al (2019) Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Hematol Oncol 37(5):578\u2013585","journal-title":"Hematol Oncol"},{"issue":"6","key":"5559_CR15","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/s41375-020-01042-y","volume":"35","author":"Y Yang","year":"2021","unstructured":"Yang Y et al (2021) Progression-free survival at 24 months and subsequent survival of patients with extranodal NK\/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia 35(6):1671\u20131682","journal-title":"Leukemia"},{"issue":"12","key":"5559_CR16","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1007\/s00277-020-04195-z","volume":"99","author":"H Chen","year":"2020","unstructured":"Chen H et al (2020) Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma. Ann Hematol 99(12):2847\u20132857","journal-title":"Ann Hematol"},{"issue":"2","key":"5559_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4143\/crt.2021.270","volume":"54","author":"YR Kim","year":"2022","unstructured":"Kim YR et al (2022) Predictive factors of event-free survival at 24 months in patients with peripheral T-cell lymphoma: A retrospective study. Cancer Res Treat 54(2):613\u2013620","journal-title":"Cancer Res Treat"},{"issue":"19","key":"5559_CR18","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1002\/cncr.30795","volume":"123","author":"M Provencio","year":"2017","unstructured":"Provencio M et al (2017) Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish lymphoma oncology group. Cancer 123(19):3709\u20133716","journal-title":"Cancer"},{"issue":"21","key":"5559_CR19","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","volume":"34","author":"G Hapgood","year":"2016","unstructured":"Hapgood G et al (2016) evaluation of the risk of relapse in classical hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol 34(21):2493\u20132500","journal-title":"J Clin Oncol"},{"issue":"8","key":"5559_CR20","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(8):1766\u20131771","journal-title":"Ann Oncol"},{"issue":"3","key":"5559_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S et al (2022) The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33(3):288\u2013298","journal-title":"Ann Oncol"},{"issue":"26","key":"5559_CR22","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ et al (2021) A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood 138(26):2828\u20132837","journal-title":"Blood"},{"issue":"8","key":"5559_CR23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM et al (2018) Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131(8):888\u2013898","journal-title":"Blood"},{"key":"5559_CR24","doi-asserted-by":"crossref","unstructured":"Huen A et al (2020) Phase I\/Ib study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 Inhibitor in patients with relapsed\/refractory T-cell lymphoma. Cancers (Basel) 12(8):2293","DOI":"10.3390\/cancers12082293"},{"issue":"4","key":"5559_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"6","key":"5559_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","volume":"19","author":"SK Barta","year":"2019","unstructured":"Barta SK et al (2019) Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk 19(6):356-364.e3","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"5559_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park SI et al (2019) The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer 125(9):1507\u20131517","journal-title":"Cancer"},{"issue":"2","key":"5559_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.24223","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ et al (2016) Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol 91(2):179\u2013184","journal-title":"Am J Hematol"},{"issue":"8","key":"5559_CR29","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1038\/bcj.2015.69","volume":"5","author":"AJ Novak","year":"2015","unstructured":"Novak AJ et al (2015) Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J 5(8):e346","journal-title":"Blood Cancer J"},{"issue":"1","key":"5559_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E et al (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132(1):49\u201358","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05559-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T05:04:59Z","timestamp":1707887099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05559-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5559"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05559-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The all authors declare that they have no conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}